Local delivery of recombinant adenovirus expressing hepatitis B virus X protein and interleukin-12 results in antitumor effects via inhibition of hepatoma cell growth and intervention of tumor microenvironment

International Journal of Molecular Medicine

Volumn 30, Issue 3, 2012, Pages 599-605

  He, Hong ^a   Fan, Ping ^a   Yin, Tao ^a   Chen, Qiaoling ^a   Shi, Huashan ^a   Liu, Sijia ^a   Li, Haoyu ^b   Jing, Qiuping ^a   Yan, Yingying ^a   Zhang, Hailong ^a   Yang, Li ^a   Wen, Yanjun ^a   Li, Yuhua ^a   Cheng, Ping ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Anti angiogenic; Hepatitis B virus X protein; Hepatocellular carcinoma; Mouse interleukin 12; Tumor microenvironment

Indexed keywords

HEPATITIS B VIRUS X PROTEIN; RECOMBINANT INTERLEUKIN 12;

ADENOVIRUS; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL; CANCER GROWTH; CD8+ T LYMPHOCYTE; CELL GROWTH; CONTROLLED STUDY; DENDRITIC CELL; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MACROPHAGE; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DENDRITIC CELLS; ENDOTHELIAL CELLS; FEMALE; GENE THERAPY; GENETIC VECTORS; INTERLEUKIN-12; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MICE; MICE, INBRED C57BL; TRANS-ACTIVATORS; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84865171102     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1027     Document Type: Article

References (40)

1. Beasley RP: Rocks along the road to the control of HBV and HCC. Ann Epidemiol 19: 231-234, 2009.
2. Okuda K: Hepatocellular carcinoma. J Hepatol 32: 225-237, 2000.
3. Tang H, Oishi N, Kaneko S and Murakami S: Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci 97: 977-983, 2006. (Pubitemid 44322542)
4. Cheng P, Li Y, Yang L, et al: Hepatitis B virus X protein (HBx) induces G2/M arrest and apoptosis through sustained activation of cyclin B1-CDK1 kinase. Oncol Rep 22: 1101-1107, 2009.
5. Tian T, Nan KJ, Wang SH, et al: PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells. Carcinogenesis 31: 1211-1219, 2010.
6. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M and Bosch J: Angiogenesis in liver disease. J Hepatol 50: 604-620, 2009.
7. Liu L, Cao Y, Chen C, et al: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858, 2006. (Pubitemid 46094197)
8. Chen X, Lin X, Zhao J, et al: A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther 16: 749-756, 2008. (Pubitemid 351426177)
9. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G and Colombo MP: Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 65: 3437-3446, 2005. (Pubitemid 40524630)
10. + T cells in xenografted nude mice. J Immunol 170: 1183-1190, 2003.
11. Li Y, Cheng P, Wen Y, et al: T lymphocyte responses against hepatitis B virus-related hepatocellular carcinoma induced by adenovirus vaccine encoding HBx. Int J Mol Med 26: 869-876, 2010.
12. Ding FX, Wang F, Lu YM, et al: Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma. Hepatology 49: 1492-1502, 2009.
13. Wang YJ, Hou Y, Huang H, Liu GR, White AP and Liu SL: Two oral HBx vaccines delivered by live attenuated Salmonella: both eliciting effective anti-tumor immunity. Cancer Lett 263: 67-76, 2008.
14. Hombach A, Heuser C and Abken H: Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis. Int J Cancer 115: 241-247, 2005. (Pubitemid 40586732)
15. Halin C, Rondini S, Nilsson F, et al: Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 20: 264-269, 2002. (Pubitemid 34205419)
16. Peng LS, Penichet ML and Morrison SL: A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J Immunol 163: 250-258, 1999. (Pubitemid 29295848)
17. Hendrzak JA and Brunda MJ: Antitumor and antimetastatic activity of interleukin-12. Curr Top Microbiol Immunol 213: 65-83, 1996. (Pubitemid 26165098)
18. Trinchieri G: Immunobiology of interleukin-12. Immunol Res 17: 269-278, 1998.
19. + GCV and IL-12 in an orthotopic mouse model for prostate cancer. Prostate Cancer Prostatic Dis 4: 44-51, 2001.
20. Couglin CM, Salhang KE, Wysocka M, et al: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 101: 1441-1452, 1998. (Pubitemid 28145262)
21. Pützer BM, Hitt M, Muller WJ, et al: Interleukin 12 and B7-1 co-stimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci USA 94: 10889-10895, 1997.
22. Bui JD, Uppaluri R, Hsieh CS and Schreiber RD: Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res 66: 7301-7309, 2006. (Pubitemid 44197712)
23. Kortylewski M, Swiderski P, Herrmann A, et al: In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 27: 925-932, 2009.
24. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H and Yu H: Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118: 3367-3377, 2008.
25. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002. (Pubitemid 36019639)
26. Mantovani A, Sozzani S, Locati M, Allavena P and Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555, 2002. (Pubitemid 35223554)
27. Rodriguez PC, Ernstoff MS, Hernandez C, et al: Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69: 1553-1560, 2009.
28. + T cell function via L-arginine metabolism. Cancer Res 69: 3086-3094, 2009.
29. + tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 67: 354-361, 2007.
30. Menon AG, Fleuren GJ, Alphenaar EA, et al: A basal membrane-like structure surrounding tumour nodules may prevent intraepithelial leucocyte infiltration in colorectal cancer. Cancer Immunol Immunother 52: 121-126, 2003.
31. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102: 18538-18543, 2005.
32. Zhang L, Conejo-Garcia JR, Katsaros D, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213, 2003. (Pubitemid 36077915)
33. Simma O, Zebedin E, Neugebauer N, et al: Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance. Cancer Res 69: 203-211, 2009.
34. Torrero MN, Xia X, Henk W, Yu S and Li S: Stat1 deficiency in the host enhances interleukin-12-mediated tumor regression. Cancer Res 66: 4461-4467, 2006.
35. Kanzler H, Barrat FJ, Hessel EM and Coffman RL: Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13: 552-559, 2007. (Pubitemid 46830615)
36. Barchet W, Wimmenauer V, Schlee M and Hartmann G: Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr Opin Immunol 20: 389-395, 2008.
37. Tannenbaum CS, Wicker N, Armstrong D, et al: Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 156: 693-699, 1996. (Pubitemid 26029621)
38. Adris S, Chuluyan E, Bravo A, et al: Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells. Cancer Res 60: 6696-6703, 2000.
39. Nastala CL, Edington HD, McKinney TG, et al: Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153: 1697-1706, 1994. (Pubitemid 24251114)
40. Luster AD and Leder P: IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 178: 1057-1065, 1993. (Pubitemid 23260444)